aminolevulinic acid has been researched along with Tyrosinemias in 4 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
Tyrosinemias: A group of disorders which have in common elevations of tyrosine in the blood and urine secondary to an enzyme deficiency. Type I tyrosinemia features episodic weakness, self-mutilation, hepatic necrosis, renal tubular injury, and seizures and is caused by a deficiency of the enzyme fumarylacetoacetase. Type II tyrosinemia features INTELLECTUAL DISABILITY, painful corneal ulcers, and keratoses of the palms and plantar surfaces and is caused by a deficiency of the enzyme TYROSINE TRANSAMINASE. Type III tyrosinemia features INTELLECTUAL DISABILITY and is caused by a deficiency of the enzyme 4-HYDROXYPHENYLPYRUVATE DIOXYGENASE. (Menkes, Textbook of Child Neurology, 5th ed, pp42-3)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Attacks of neuropathic pain, usually abdominal, are characteristic of the acute porphyrias and accompanied by overproduction of heme-precursor molecules, specifically delta-aminolevulinic acid and porphobilinogen." | 7.81 | Role of delta-aminolevulinic acid in the symptoms of acute porphyria. ( Bissell, DM; Blanc, PD; Lai, JC; Meister, RK, 2015) |
| "There is now convincing evidence that delta-aminolevulinic acid is the cause of pain in the acute porphyrias." | 7.81 | Role of delta-aminolevulinic acid in the symptoms of acute porphyria. ( Bissell, DM; Blanc, PD; Lai, JC; Meister, RK, 2015) |
| "Attacks of neuropathic pain, usually abdominal, are characteristic of the acute porphyrias and accompanied by overproduction of heme-precursor molecules, specifically delta-aminolevulinic acid and porphobilinogen." | 5.42 | Role of delta-aminolevulinic acid in the symptoms of acute porphyria. ( Bissell, DM; Blanc, PD; Lai, JC; Meister, RK, 2015) |
| "We review genetic acute porphyria, hereditary tyrosinemia, and an acquired condition, lead poisoning." | 5.42 | Role of delta-aminolevulinic acid in the symptoms of acute porphyria. ( Bissell, DM; Blanc, PD; Lai, JC; Meister, RK, 2015) |
| "Attacks of neuropathic pain, usually abdominal, are characteristic of the acute porphyrias and accompanied by overproduction of heme-precursor molecules, specifically delta-aminolevulinic acid and porphobilinogen." | 3.81 | Role of delta-aminolevulinic acid in the symptoms of acute porphyria. ( Bissell, DM; Blanc, PD; Lai, JC; Meister, RK, 2015) |
| "There is now convincing evidence that delta-aminolevulinic acid is the cause of pain in the acute porphyrias." | 3.81 | Role of delta-aminolevulinic acid in the symptoms of acute porphyria. ( Bissell, DM; Blanc, PD; Lai, JC; Meister, RK, 2015) |
| "Attacks of neuropathic pain, usually abdominal, are characteristic of the acute porphyrias and accompanied by overproduction of heme-precursor molecules, specifically delta-aminolevulinic acid and porphobilinogen." | 1.42 | Role of delta-aminolevulinic acid in the symptoms of acute porphyria. ( Bissell, DM; Blanc, PD; Lai, JC; Meister, RK, 2015) |
| "We review genetic acute porphyria, hereditary tyrosinemia, and an acquired condition, lead poisoning." | 1.42 | Role of delta-aminolevulinic acid in the symptoms of acute porphyria. ( Bissell, DM; Blanc, PD; Lai, JC; Meister, RK, 2015) |
| "The chemical diagnosis of tyrosinemia type I generally involves the detection of succinylacetone (SA) in patient urine." | 1.33 | Stability of 5-aminolevulinic acid on dried urine filter paper for a diagnostic marker of tyrosinemia type I. ( Inoue, Y; Kuhara, T; Ohse, M; Shinka, T, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bissell, DM | 1 |
| Lai, JC | 1 |
| Meister, RK | 1 |
| Blanc, PD | 1 |
| Shinka, T | 2 |
| Kuhara, T | 2 |
| Ohse, M | 1 |
| Inoue, Y | 1 |
| Erskine, PT | 1 |
| Newbold, R | 1 |
| Brindley, AA | 1 |
| Wood, SP | 1 |
| Shoolingin-Jordan, PM | 1 |
| Warren, MJ | 1 |
| Cooper, JB | 1 |
4 other studies available for aminolevulinic acid and Tyrosinemias
| Article | Year |
|---|---|
Role of delta-aminolevulinic acid in the symptoms of acute porphyria.
Topics: Abdominal Pain; Adult; Aminolevulinic Acid; Chelation Therapy; Diagnosis, Differential; Female; Heme | 2015 |
Quantification of urinary 5-aminolevulinic acid by gas chromatography-mass spectrometry.
Topics: Aminolevulinic Acid; Gas Chromatography-Mass Spectrometry; Humans; Reference Standards; Tyrosinemias | 2004 |
Stability of 5-aminolevulinic acid on dried urine filter paper for a diagnostic marker of tyrosinemia type I.
Topics: Aminolevulinic Acid; Biomarkers; Filtration; Gas Chromatography-Mass Spectrometry; Humans; Reproduci | 2005 |
The x-ray structure of yeast 5-aminolaevulinic acid dehydratase complexed with substrate and three inhibitors.
Topics: Aminolevulinic Acid; Binding, Competitive; Catalytic Domain; Crystallography, X-Ray; Enzyme Inhibito | 2001 |